Current status on M. pneumoniae: Clinical Features and Management Strategies

Background: The COVID-19 pandemic has significantly impacted Mycoplasma pneumoniae (MP), leading to a decline in prevalence and delayed resurgence. The rise of macrolide-resistant M. pneumoniae complicates treatment, necessitating alternative antibiotics. Aim: This review examines the impact of COVID-19 on M. pneumoniae (MP) epidemiology, rising macrolide resistance, and evolving treatment challenges. It highlights advanced diagnostics, alternative antibiotics, and future research needs for predictive biomarkers and novel therapies. Continuous surveillance and adaptive strategies are crucial for optimizing MP infection management in a post-pandemic world. Methods: A comprehensive review of recent literature was conducted, focusing on epidemiological trends, antimicrobial resistance patterns, diagnostic innovations, and treatment strategies for MP infections. Data were extracted from peer-reviewed journals, clinical studies, and global health reports to provide an updated perspective on the evolving landscape of MP infections. Results: M. pneumoniae infections, which declined during COVID-19 due to non-pharmaceutical interventions, have resurged post-pandemic due to macrolide-resistant infections. Rapid molecular diagnostic tools and predictive biomarkers are needed to improve treatment outcomes and optimize infection management in pediatric patients. Conclusion: Managing MP infections in a post-pandemic world requires continuous surveillance, advanced diagnostics, and adaptive treatment strategies. The increasing prevalence of MRMP underscores the need for alternative therapeutic options and robust antimicrobial stewardship. Future research should focus on predictive factors for treatment response, novel drug development, and the long-term impact of epidemiological shifts on respiratory infections.